1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: CAR-T Therapies for Blood Cancers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. CAR-T Therapies for Blood Cancers Market, by Target Antigen
8.1.1. CD19-targeted CAR-T Therapies
8.1.1.1. Market Revenue and Forecast
8.1.2. BCMA-targeted CAR-T Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. CD20-targeted CAR-T Therapies
8.1.3.1. Market Revenue and Forecast
8.1.4. Dual-target & Multi-antigen CAR-T Therapies
8.1.4.1. Market Revenue and Forecast
9.1. CAR-T Therapies for Blood Cancers Market, by Cancer Type
9.1.1. Acute Lymphoblastic Leukemia (ALL)
9.1.1.1. Market Revenue and Forecast
9.1.2. Diffuse Large B-Cell Lymphoma (DLBCL)
9.1.2.1. Market Revenue and Forecast
9.1.3. Multiple Myeloma
9.1.3.1. Market Revenue and Forecast
9.1.4. Chronic Lymphocytic Leukemia (CLL)
9.1.4.1. Market Revenue and Forecast
9.1.5. Other Hematologic Malignancies
9.1.5.1. Market Revenue and Forecast
10.1. CAR-T Therapies for Blood Cancers Market, by Therapy Type
10.1.1. Autologous CAR-T Therapies
10.1.1.1. Market Revenue and Forecast
10.1.2. Allogeneic (Off-the-shelf) CAR-T Therapies
10.1.2.1. Market Revenue and Forecast
11.1. CAR-T Therapies for Blood Cancers Market, by End-Use
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Cancer Treatment Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. CAR-T Therapies for Blood Cancers Market, by Manufacturing Type
12.1.1. In-house Manufacturing
12.1.1.1. Market Revenue and Forecast
12.1.2. Contract Manufacturing (CDMO-based)
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Target Antigen
13.1.2. Market Revenue and Forecast, by Cancer Type
13.1.3. Market Revenue and Forecast, by Therapy Type
13.1.4. Market Revenue and Forecast, by End-Use
13.1.5. Market Revenue and Forecast, by Manufacturing Type
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Target Antigen
13.1.6.2. Market Revenue and Forecast, by Cancer Type
13.1.6.3. Market Revenue and Forecast, by Therapy Type
13.1.6.4. Market Revenue and Forecast, by End-Use
13.1.6.5. Market Revenue and Forecast, by Manufacturing Type
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Target Antigen
13.1.7.2. Market Revenue and Forecast, by Cancer Type
13.1.7.3. Market Revenue and Forecast, by Therapy Type
13.1.7.4. Market Revenue and Forecast, by End-Use
13.1.7.5. Market Revenue and Forecast, by Manufacturing Type
13.2. Europe
13.2.1. Market Revenue and Forecast, by Target Antigen
13.2.2. Market Revenue and Forecast, by Cancer Type
13.2.3. Market Revenue and Forecast, by Therapy Type
13.2.4. Market Revenue and Forecast, by End-Use
13.2.5. Market Revenue and Forecast, by Manufacturing Type
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Target Antigen
13.2.6.2. Market Revenue and Forecast, by Cancer Type
13.2.6.3. Market Revenue and Forecast, by Therapy Type
13.2.7. Market Revenue and Forecast, by End-Use
13.2.8. Market Revenue and Forecast, by Manufacturing Type
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Target Antigen
13.2.9.2. Market Revenue and Forecast, by Cancer Type
13.2.9.3. Market Revenue and Forecast, by Therapy Type
13.2.10. Market Revenue and Forecast, by End-Use
13.2.11. Market Revenue and Forecast, by Manufacturing Type
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Target Antigen
13.2.12.2. Market Revenue and Forecast, by Cancer Type
13.2.12.3. Market Revenue and Forecast, by Therapy Type
13.2.12.4. Market Revenue and Forecast, by End-Use
13.2.13. Market Revenue and Forecast, by Manufacturing Type
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Target Antigen
13.2.14.2. Market Revenue and Forecast, by Cancer Type
13.2.14.3. Market Revenue and Forecast, by Therapy Type
13.2.14.4. Market Revenue and Forecast, by End-Use
13.2.15. Market Revenue and Forecast, by Manufacturing Type
13.3. APAC
13.3.1. Market Revenue and Forecast, by Target Antigen
13.3.2. Market Revenue and Forecast, by Cancer Type
13.3.3. Market Revenue and Forecast, by Therapy Type
13.3.4. Market Revenue and Forecast, by End-Use
13.3.5. Market Revenue and Forecast, by Manufacturing Type
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Target Antigen
13.3.6.2. Market Revenue and Forecast, by Cancer Type
13.3.6.3. Market Revenue and Forecast, by Therapy Type
13.3.6.4. Market Revenue and Forecast, by End-Use
13.3.7. Market Revenue and Forecast, by Manufacturing Type
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Target Antigen
13.3.8.2. Market Revenue and Forecast, by Cancer Type
13.3.8.3. Market Revenue and Forecast, by Therapy Type
13.3.8.4. Market Revenue and Forecast, by End-Use
13.3.9. Market Revenue and Forecast, by Manufacturing Type
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Target Antigen
13.3.10.2. Market Revenue and Forecast, by Cancer Type
13.3.10.3. Market Revenue and Forecast, by Therapy Type
13.3.10.4. Market Revenue and Forecast, by End-Use
13.3.10.5. Market Revenue and Forecast, by Manufacturing Type
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Target Antigen
13.3.11.2. Market Revenue and Forecast, by Cancer Type
13.3.11.3. Market Revenue and Forecast, by Therapy Type
13.3.11.4. Market Revenue and Forecast, by End-Use
13.3.11.5. Market Revenue and Forecast, by Manufacturing Type
13.4. MEA
13.4.1. Market Revenue and Forecast, by Target Antigen
13.4.2. Market Revenue and Forecast, by Cancer Type
13.4.3. Market Revenue and Forecast, by Therapy Type
13.4.4. Market Revenue and Forecast, by End-Use
13.4.5. Market Revenue and Forecast, by Manufacturing Type
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Target Antigen
13.4.6.2. Market Revenue and Forecast, by Cancer Type
13.4.6.3. Market Revenue and Forecast, by Therapy Type
13.4.6.4. Market Revenue and Forecast, by End-Use
13.4.7. Market Revenue and Forecast, by Manufacturing Type
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Target Antigen
13.4.8.2. Market Revenue and Forecast, by Cancer Type
13.4.8.3. Market Revenue and Forecast, by Therapy Type
13.4.8.4. Market Revenue and Forecast, by End-Use
13.4.9. Market Revenue and Forecast, by Manufacturing Type
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Target Antigen
13.4.10.2. Market Revenue and Forecast, by Cancer Type
13.4.10.3. Market Revenue and Forecast, by Therapy Type
13.4.10.4. Market Revenue and Forecast, by End-Use
13.4.10.5. Market Revenue and Forecast, by Manufacturing Type
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Target Antigen
13.4.11.2. Market Revenue and Forecast, by Cancer Type
13.4.11.3. Market Revenue and Forecast, by Therapy Type
13.4.11.4. Market Revenue and Forecast, by End-Use
13.4.11.5. Market Revenue and Forecast, by Manufacturing Type
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Target Antigen
13.5.2. Market Revenue and Forecast, by Cancer Type
13.5.3. Market Revenue and Forecast, by Therapy Type
13.5.4. Market Revenue and Forecast, by End-Use
13.5.5. Market Revenue and Forecast, by Manufacturing Type
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Target Antigen
13.5.6.2. Market Revenue and Forecast, by Cancer Type
13.5.6.3. Market Revenue and Forecast, by Therapy Type
13.5.6.4. Market Revenue and Forecast, by End-Use
13.5.7. Market Revenue and Forecast, by Manufacturing Type
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Target Antigen
13.5.8.2. Market Revenue and Forecast, by Cancer Type
13.5.8.3. Market Revenue and Forecast, by Therapy Type
13.5.8.4. Market Revenue and Forecast, by End-Use
13.5.8.5. Market Revenue and Forecast, by Manufacturing Type
14.1. Novartis AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Gilead Sciences, Inc. (Kite Pharma)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bristol Myers Squibb Company (Celgene/Juno Therapeutics)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Johnson & Johnson (Legend Biotech Corporation)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Fate Therapeutics, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Allogene Therapeutics, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Cellectis S.A.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Bluebird Bio, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Autolus Therapeutics plc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Precision BioSciences, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
